The Bullous Pemphigoid drugs in development market research report provides comprehensive information on the therapeutics under development for Bullous Pemphigoid, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bullous Pemphigoid. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Bullous Pemphigoid by 12 companies/universities/institutes. The top development phase for Bullous Pemphigoid is phase ii with six drugs in that stage. The Bullous Pemphigoid pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bullous Pemphigoid pipeline products market are: Amgen, Johnson & Johnson and Innate Pharma.

The key targets in the Bullous Pemphigoid pipeline products market include IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN), Heat Shock Protein 90 (HSP90), and Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79).

The key mechanisms of action in the Bullous Pemphigoid pipeline product include IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN) Antagonist with two drugs in Phase III. The Bullous Pemphigoid pipeline products include five routes of administration with the top ROA being Intravenous and four key molecule types in the Bullous Pemphigoid pipeline products market including Small Molecule, and Monoclonal Antibody.

Bullous Pemphigoid overview

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatories and immunosuppressants.

For a complete picture of Bullous Pemphigoid’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.